Technologies

Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL)  and a purity, at least equal to food/cosmetic grade (P≥2).

The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.

This invention comprises an interrogation and readout differential method for chemical sensors based on Surface Plasmon Resonances (SPR). The integration of the SPR sensing unit (chip or other), as intermediate reflecting element of a Fabry-Perot (FP) optical resonator, is the starting point for the application of this method.

Combinations of several enzymes in a production chain are preferred to “first generation” enzymatic processes (where the "single reaction - single enzyme" principle was followed), for the synthesis of compounds with high added value starting from simple and cheap substrates. An important requirement for obtaining control in "cascade enzymatic reactions" is the ability to deliver from one biocatalyst to the next one the various intermediates, limiting as much as possible the diffusion of the latter in the solvent.

Celiac disease and non-celiac gluten sensitivity affect a large portion of the world population. Furthermore, the percentage of people who adopt the gluten free diet is constantly increasing because it is perceived to be healthier. We have previously developed a food grade enzymatic procedure (transamidation) for wheat flour capable of making gluten unable to induce the inflammatory response in the intestine of celiac disease patients.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.